由来生物
goat
品質水準
結合体
unconjugated
抗体製品の状態
affinity isolated antibody
抗体製品タイプ
primary antibodies
クローン
polyclonal
形状
lyophilized powder
化学種の反応性
human
テクニック
immunohistochemistry: 0.5-5 μg/mL
neutralization: suitable
western blot: 0.1-0.2 μg/mL
UniProtアクセッション番号
保管温度
−20°C
遺伝子情報
human ... IL1A(3552)
類似した製品をお探しですか？ 訪問 製品比較ガイド
詳細
Interleukins are proinflammatory cytokines produced on cell injury or trauma. There are two closely related types of interleukins produced by the cell, IL-1α and IL-1β that are produced by the activation of NF-κ B transcription factor in response to bacterial infection or LPS. Both IL-1α and IL-1β exert their cellular effects by signalling through IL-1 receptor type 1. A variety of cells such as macrophages, epithelial cells, fibroblasts, keratinocytes, monocytes and dendritic cells secrete IL-1α. Both IL-1α and IL-1β are important in acquired immunity, inflammation, response to infection and production of matrix metalloproteinases (MMPs). The effects of IL-1α are mediated by activation of NF-κB, JNK and MAPK pathways that activated the genes in response to infection and inflammation. Overproduction of IL-1α has been implicated in inflammatory disorders like rheumatoid arthritis and periodontitis
Anti-interleukin-1α specifically reacts with human IL-1α. It does not react with human IL-1β and mouse IL-1β or mouse IL-1α.
Anti-interleukin-1α specifically reacts with human IL-1α. It does not react with human IL-1β and mouse IL-1β or mouse IL-1α.
免疫原
purified, E. coli-derived recombinant human interleukin-1α.
アプリケーション
Anti-interleukin 1α antibody may be used for immunoblotting at a working concentration of 0.1-0.2 μg/ml. For immunohistochemistry the recommended concentration is 0.5-5 μg/ml. The antibody is suitable for neutralization reactions.
物理的形状
凍結乾燥品(PBS溶液, 5%トレハロース含有, 0.2 μmフィルター滅菌済み)。
免責事項
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
適切な製品が見つかりませんか。
製品選択ツール.をお試しください
関連製品
製品番号
詳細
価格
試験成績書（COA）
製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
Interleukin-1, inflammasomes, autoinflammation and the skin
Contassot E et al
Swiss Medical Weekly, 142, w13590-w13590 (2010)
Interleukin-1 (IL-1) pathway
Weber A et al
Science Signaling, 3, p-p (2010)
S Z Ben-Sasson et al.
Cytokine, 56(1), 122-125 (2011-08-17)
IL-1 strikingly enhances antigen-driven responses of CD4 and CD8 T cells. It is substantially more effective than LPS and when added to a priming regime of antigen plus LPS, it strikingly enhances cell expansion. The effect is mediated by direct
Charles A Dinarello
Current opinion in pharmacology, 4(4), 378-385 (2004-07-15)
All biological agents currently used for reducing TNFalpha activity in disease are neutralization strategies; however, there are several strategies for reducing interleukin (IL)-1 activities: the IL-1 receptor antagonist (IL-1Ra), anti-IL-1beta monoclonal antibodies, the IL-1 Trap, IL-1 receptor type I antibodies
H E Barksby et al.
Clinical and experimental immunology, 149(2), 217-225 (2007-06-26)
Understanding cytokine immunobiology is central to the development of rational therapies for destructive inflammatory diseases such as rheumatoid arthritis (RA) and periodontitis. The classical interleukin-1 (IL-1) family cytokines, IL-1alpha and IL-1beta, as well as IL-18, play key roles in inflammation.
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）